Treatment of Infective Endocarditis Due to Methicillin-Resistant Staphylococci
Clinical scenario: Infective endocarditis caused by methicillin-resistant staphylococci — an organism that requires a specific antibiotic strategy distinct from methicillin-susceptible infections. The approach differs further depending on whether the patient has native valve endocarditis (NVE) or prosthetic valve endocarditis (PVE).
Treatment approach
Intravenous antibiotic therapy is the cornerstone of management, with the chosen regimen and duration determined by valve type. For NVE, a single-agent or combination intravenous approach is recommended; PVE calls for a multi-drug intravenous regimen over an extended course.
Specific agents, dosing, and full duration guidance are available in the structured protocol →
References
DOI: 10.1093/eurheartj/ehad193
- In patients with NVE due to methicillin-resistant staphylococci, vancomycin is recommended for 4–6 weeks using the following doses:
- In patients with NVE due to methicillin-resistant staphylococci, daptomycin combined with cloxacillin, ceftaroline or fosfomycin may be considered using the following doses:
- In patients with PVE due to methicillin-resistant staphylococci, vancomycin with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:
View source ↗